Target Therapy for Colorectal Cancer

대장암의 표적치료

  • Lee, Kyung-Hee (Department of Internal Medicine, College of Medicine, Yeungnam University)
  • 이경희 (영남대학교 의과대학 내과학교실)
  • Published : 2006.12.30


In the past decade, the median duration of survival among patients with advanced colorectal cancer has increased from 12 months to about 18 months, primarily as a results of the introduction of irinotecan and oxaliplatin. Advances in the understanding of the molecular mechanisms underlying the development and progression of cancer have resulted in the discovery of new therapeutic interventions that target specific molecular abnormalities. Their specificity, and therefore their potential to bind preferentially and modify tumor-specific targets, sparing normal tissues and causing fewer side-effects compared to conventional cytotoxic agents, makes them an attractive therapeutic option. The future of this approach for the treatment of solid tumors is promising.